Investment 24 February 2026 - 25 February 2026

Palantir stock price slides after software rout; investors eye Nvidia and inflation data
···

Palantir stock price slides after software rout; investors eye Nvidia and inflation data

Palantir shares fell 3.4% to $128.75 Tuesday, cutting its market value to $433 billion amid a broad selloff in software stocks. The iShares Expanded Tech-Software ETF dropped 4.7%, while Snowflake, Datadog, and CrowdStrike also posted steep losses. Investors cited AI disruption risk and a viral research note predicting job losses. Nvidia’s earnings and U.S. inflation data are expected later this week.
February 24, 2026
Texas Instruments stock sinks during capital management call — here’s what investors are zeroing in on
···

Texas Instruments stock sinks during capital management call — here’s what investors are zeroing in on

Texas Instruments shares fell 3.6% to $211.95 Tuesday after the company detailed 2026 capital spending plans and reaffirmed a $2–$3 billion capex range. TI said it aims to source over 95% of wafers internally by 2030 and will fund its Silicon Labs acquisition with cash and prearranged debt. Cantor Fitzgerald raised its target price to $250 but maintained a Neutral rating.
February 24, 2026
Lincoln National stock tries to steady after 10% slide as traders eye rates and analyst calls
···

Lincoln National stock tries to steady after 10% slide as traders eye rates and analyst calls

Lincoln National shares rose about 1% to $36.05 Tuesday after plunging 10.6% on heavy volume Monday, outpacing declines in other major life insurers. Morgan Stanley trimmed its price target to $50 but kept an overweight rating. Monday’s trading volume hit 5.3 million shares, nearly triple the average. A regulatory filing showed a restricted stock grant to an executive, not open-market buying.
February 24, 2026
Tidewater stock jumps before U.S. open after $500 million Brazil vessel deal
···

Tidewater stock jumps before U.S. open after $500 million Brazil vessel deal

Tidewater shares rose 7.6% to $78.91 in extended trading after it agreed to buy Brazil’s Wilson Sons Ultratug Offshore and Atlantic Offshore Services for about $500 million, including debt. The deal adds 22 platform supply vessels and $441 million in contracted backlog. Tidewater expects $220 million in revenue from the acquired business in the first year. Investors await Brazil antitrust and lender approvals before a late-Q2 close.
February 24, 2026
Arcellx stock jumps toward $115 on Gilead’s $7.8 billion buyout — what investors watch next
···

Arcellx stock jumps toward $115 on Gilead’s $7.8 billion buyout — what investors watch next

Arcellx shares traded near $113.75 premarket Tuesday after soaring 77% on news of Gilead’s $115-per-share cash offer. The deal includes a possible $5 per share contingent payout tied to anito-cel sales through 2029. Gilead will launch a tender offer; the FDA’s decision deadline for anito-cel is Dec. 23, 2026. The $5 payout depends on anito-cel reaching $6 billion in global sales by 2029.
February 24, 2026
Halma share price hits fresh 52-week high as HLMA outperforms in early London trade
···

Halma share price hits fresh 52-week high as HLMA outperforms in early London trade

Halma shares hit a 52-week high of 4,052 pence in early London trading Tuesday, up 1.8%, valuing the group at about £15.3 billion. No new company statement was issued, with the next update due March 12. European stocks slipped as tariff and AI concerns weighed on sentiment. Halma’s last major guidance in November projected mid-teens organic revenue growth and a 22% adjusted EBIT margin.
February 24, 2026
Johnson Matthey share price steadies after Honeywell deal cut — what investors watch next
···

Johnson Matthey share price steadies after Honeywell deal cut — what investors watch next

Johnson Matthey shares stabilized Tuesday after plunging 16.4% on news it cut the sale price of its Catalyst Technologies unit to Honeywell to £1.325 billion. The company now expects to return about £1 billion to shareholders, including an £800 million special dividend. CEO Liam Condon bought 5,226 shares after the selloff. The deal’s long-stop date moved to July 21, pending regulatory approval.
February 24, 2026
Legal & General share price slips as $1 billion debt-for-nature plan lands
···

Legal & General share price slips as $1 billion debt-for-nature plan lands

Legal & General shares fell 0.4% to 268.0p in early London trading after announcing a $1 billion, five-year partnership with Enosis Capital to invest in emerging-market debt swaps. The stock had closed at 269.1p on Monday after hitting a 12-month high of 279.5p. Investors await the company’s full-year results on March 11 for more details on capital allocation and deal returns.
February 24, 2026
BAE Systems share price ticks up as buyback rolls on — what investors watch next for LSE:BA
···

BAE Systems share price ticks up as buyback rolls on — what investors watch next for LSE:BA

BAE Systems shares rose 0.3% to 2,144 pence in early London trading Tuesday, recovering after a 1.3% drop Monday. The company disclosed it bought back 83,422 shares at an average price of 2,152.31 pence, bringing total repurchases in the current tranche to over 17.5 million shares. Investors focused on buybacks as sector earnings and policy signals loom.
February 24, 2026
Woodside Energy stock jumps to 19-month high on profit beat — dividend dates and LNG stake sale in focus
···

Woodside Energy stock jumps to 19-month high on profit beat — dividend dates and LNG stake sale in focus

Woodside Energy shares rose 2.6% after 2025 underlying profit reached US$2.65 billion, beating estimates. The company declared a final dividend of 59 US cents, with shares going ex-dividend March 5. Investors are watching talks to sell a further stake in the Louisiana LNG project and monitoring Scarborough project delivery. Reported net profit after tax fell 24% to US$2.72 billion.
February 24, 2026
1 … 34 35 36 37 38 … 46

Stock Market Today

  • Bell Potter Sees Potential 100%+ Gain in Imugene ASX Healthcare Stock
    May 28, 2026, 7:13 PM EDT. Imugene Ltd (ASX: IMU) shares surged after Bell Potter highlighted progress in its Phase 1b trial targeting rare Non-Hodgkin's Lymphoma (NHL). The trial tests azer-cel combined with BTKi drugs, aiming to improve treatment for patients resistant to previous therapies. Bell Potter is optimistic, citing high response rates in related studies and the advantage of the off-the-shelf availability of azer-cel. The broker expects rapid enrolment and early data within weeks, reaffirming a speculative buy rating with a 25 cent price target, over double the current share price. Imugene addresses a critical unmet medical need, positioning it as a notable ASX healthcare stock with significant upside potential.